The estrogen receptor alpha (ERα) is routinely assessed in breast cancer to inform clinical management. More recently, the androgen receptor (AR) has been shown to be of potential prognostic value, but the appropriate cut-point for robust prognostication has yet to be established.
Statement of Translational Relevance
The estrogen receptor alpha (ERα) is routinely assessed in breast cancer to inform clinical management. More recently, the androgen receptor (AR) has been shown to be of potential prognostic value, but the appropriate cut-point for robust prognostication has yet to be established.
In this study, an optimal cut-point for AR was determined using ROC analysis with a test cohort and its prognostic capacity validated in an independent cohort. Prognostic capacity was robust with a high (78% positivity) cut-point but not with lower (1% -10%) positivity cut-points commonly used in previous studies. The 78% cut-point was valid for unselected cases and selected ERα positive cases. Among the latter, an AR:ERα positivity ratio indicative of comparable receptor expression or AR predominance was associated with the best survival outcome. Determination of
Introduction
Androgen receptor (AR) expression is highly prevalent in primary breast cancers, ranging from 53-99% depending on the characteristics of the cohort analyzed, the assay methodology and the criteria for positivity (1) (2) (3) (4) (5) (6) (7) . Up to 90% of estrogen receptor alpha (ERα) positive tumors and approximately 20% of ERα negative tumors are also AR positive (1) (2) (3) (4) (5) (6) (7) . Given the high frequency of AR expression in breast cancer and the availability of old and new generation agents to modulate its activity, there has been a resurgence of interest in targeting the AR signaling pathway to treat women with this disease. However, much controversy exists over how best to target AR in breast cancer as it appears to have pleiotropic roles dependent on disease subtype and stage of progression (reviewed in (8) and (9)). Strong clinical and preclinical evidence supports AR as being growth inhibitory in hormone sensitive, ER positive breast malignancies, a role that may be sustained from normal breast tissue as AR activity inhibits breast development in men and women (8, 10) . Accordingly, non-aromatizable AR agonists such as fluoxymesterone have historically demonstrated an efficacy comparable to that of the selective ER modulator, tamoxifen, in advanced breast cancer (11, 12) . However, use of androgenic agents was discontinued due to virilizing side effects in some women. Development of new selective AR modulators (SARMs) with AR agonist activity in breast tissues may circumvent that problem and one, Enobosarm (GTx024), has shown promise in a phase II trial of women with advanced, hormone sensitive disease (13) . This approach is supported by a recent preclinical study in which induction of AR agonist activity using a different SARM inhibited the growth of endocrine-sensitive as well as endocrine-resistant patient-derived breast cancer xenografts (14) . However, some pre-clinical studies have suggested that AR antagonism is also a therapeutic option for women with ERα positive disease (15) (16) (17) Author Manuscript Published OnlineFirst on March 7, 2018 ; DOI: 10.1158/1078-0432.CCR- purported to have oncogenic activity (18) (19) (20) (21) (22) (23) (24) . However, at µM concentrations AR antagonists can have off-target effects in breast cancer cells (25) , suggesting that their therapeutic efficacy may not be mediated by inhibition of AR.
Numerous studies have investigated whether AR is a biomarker for predicting survival of breast cancer, but like the potential utility and means of targeting AR, its prognostic value remains controversial. Disparate results among studies may be attributed to heterogeneity of breast cancer cohorts and differences in methodology, including the use of different cut-points for AR positivity.
Although several meta-analyses commonly conclude that AR is associated with better outcomes in ERα positive disease (26) (27) (28) (29) , these analyses used population-level rather than individual patientlevel data. Moreover, most studies included in the meta-analyses of AR as a prognostic biomarker used cut-points that are typically those used for ERα and progesterone receptor (PR) as a predictive biomarker (30, 31). To date, no standardized cut-point for AR prognostication has been statistically defined, which most likely has contributed to conflicting results in the literature regarding AR as a prognostic biomarker in breast cancer.
In the current study, we comprehensively reviewed the literature on AR prognostication for breast cancer survival to highlight methodological heterogeneity in previous studies, and utilized two clinically validated breast cancer cohorts from Australia (32) and Canada (33) with long-term follow-up to empirically define optimal criteria for AR to be a robust independent predictor of breast cancer specific survival. Since there has been interest in assessing the clinical relevance of different AR to ERα expression ratios in breast cancer (8, 15, 34, 35) , we also evaluated this parameter.
Methods

Study selection for comprehensive review on AR and breast cancer specific outcome
Primary publications that investigated the relationship between AR expression and breast cancer outcome were identified by searching PubMed with the terms 'breast cancer' and 'androgen receptor' up to July 2017. Only studies that examined the relationship between AR level and patient outcome were included; there was no restriction based on methodology used to assess AR protein levels. Exclusion criteria for the PubMed search included the following 1) non-English articles, 2) review articles, 3) no information provided for at least one of the following: disease free survival (DFS), relapse-free survival (RFS) or breast cancer specific overall survival (OS) and 4) duplicate publications/cohorts. Our comprehensive review identified a total of 53 articles (Table 1) . Articles were divided into 3 cohort subtypes: (1) unselected (i.e. all cases); (2) ERα positive and (3) ERα negative cohorts, including TNBC. 7 training cohort) and AR-N20 (SC-816, epitope: amino acids 1-20; Santa Cruz; Dallas, TX) for the validation cohort. The specificity of both of these AR antibodies has been confirmed previously by western blot and peptide competition experiments (36, 37) . Concordance of immunostaining with the two AR antibodies is shown in Supplementary Figure 1 . Details of the AR immunohistochemistry methodology and scoring are contained in Supplementary Methods. Ki67 (SP6, Neomarkers, USA; 1:200 dilution) was scored as a visual estimate of continuous percent positivity by a board certified clinical pathologist for both cohorts (38, 39) .
ROC Analysis
ROC analysis was used to dichotomize AR and Ki67 positivity for all cases in the individual training and validation cohorts. Additional ROC analyses were performed for all cases and the ERα positive cases in the combined training and validation cohort. There were insufficient cases in the combined cohort to perform ROC analyses for HER2+ or ERα negative sub-groups. The optimal cut-points for predicting breast cancer death were determined using the Youden index (J), which was calculated using the formula J = max [sensitivity + specificity-1] (40). In addition to ROC analysis, recursive partitioning was applied to the training cohort to select the most appropriate AR cut-point (41) . For additional details of the statistical analyses see Supplementary Methods.
Statistical power of the ROC-derived AR cut-point for each of the cohorts was determined using Minitab 17 (www.minitab.com, USA).
Ten-fold Cross Validation
Ten-fold cross validation was performed to provide evidence of the accuracy of the classifier model to correctly predict the AR classes generated by ROC analysis (42) (43) (44) . To this end, we employed supervised learning to build a range of classifiers including Decision Stump, Decision Tree, Decision Tree with information gain and Naïve Bayse from cohort features such as tumor size and overall survival. Ten-fold cross-validation randomly divides the dataset into 10 sub-samples and uses 9 sub-samples as training data and one sub-sample as test data. This process is repeated 10-times. Cross-validation is a reliable statistic in supervised learning and class prediction as it avoids overlapping test sets. The above-mentioned analyses were performed using RapidMiner 6.0 software (RapidMiner, Boston, USA).
Results
A comprehensive analysis of studies investigating AR as a biomarker of breast cancer survival
A comprehensive review of the literature on AR as a prognostic factor in breast cancer was undertaken. A total of 53 studies that assessed AR status and disease outcome in breast cancer using either radio-ligand binding assays (n=7), immunostaining (n=45), or reverse phase protein microarray (n=1) were identified in a PubMed search with the criteria outlined in Methods (Table   1 ). Of these, 7 did not perform multivariate analyses. AR was predictive of breast cancer outcome in 22/46 (48%) of all previous studies that performed multivariate analyses. Nearly all previous studies used cut-points of 1% or 10% nuclear AR positivity. Among the 22 studies involving unselected breast cancer cohorts, most found that AR is prognostic for OS by univariate analysis, but only 10/22 (45%) identified AR as an independent prognostic marker of OS by multivariate analyses (Table 1) . Among the 8 studies involving cohorts selected for ERα positive disease, 5/8 (62%) identified AR as an independent predictor of outcome. Findings in cohorts selected for ER negative disease were most conflicting, with a significant association between AR expression and OS reported in only 7/18 (39%) of studies. Of note, 5 of these 7 studies (45) (46) (47) (48) (49) reported that AR expression conferred a survival advantage in tumors that lacked ER expression, but 2 (50, 51) reported a survival disadvantage (Table 1) . Collectively, the studies published to date highlight the lack of consensus on whether AR is an independent prognostic factor for breast cancer survival in unselected or selected cohorts. Importantly, none of the published studies performed ROC analysis or used an alternative statistical approach to define the optimal cut-point for AR prognostication in breast cancer. The majority of studies employed an arbitrary cut-point, the most common being 1% or 10% AR positivity. While these cut-points, commonly used for ERα and PR as a predictive biomarker (30, 31), may be useful to determine AR status, they are not necessarily optimal for use in prognostication.
Commonly used cut-points of AR positivity do not reliably predict breast cancer survival
The majority (>75%) of breast cancers in the training and validation cohorts analyzed in this study were classified as having AR positive nuclear immunostaining irrespective of whether a 1% or 10% criterion was used (Supplementary Table 1 ). ROC analysis and the generated area under the curve (AUC) for all cases was used to assess how well AR positivity could distinguish between patients that died from breast cancer and those that survived at least 10 years. AR positivity had prognostic capacity in both the training (AUC=0.678, 95% CI; 0.587-0.770, P<0.0001, Figure 1A ) and validation (AUC=0.588, 95% CI; 0.525-0.651, P=0.008, Figure 2A ) cohorts. Based on the ROC analysis, a cut-point of 1% AR positivity, used in 14/36 of previous studies (see Table 1 ), resulted in high sensitivity for predicting breast cancer OS in the training (90.0%) and validation (93.8%) cohorts, but a low specificity in both instances (training: 27.5%; validation: 7.8%). Similarly, the commonly used cut-point of 10% AR positivity (13/36 of studies in Table 1 Table 2, Table   3 ).
Defining a cut-point for AR positivity that confers robust prognostication
As neither a 1% nor a 10% cut-point for AR positivity was prognostic for breast cancer OS in both the training and validation cohorts, the Youden index method, which gives equal weight to sensitivity and specificity, was applied to the ROC analysis to identify an optimal AR cut-point for all cases in the training cohort. The highest Youden index was obtained using 77.5% AR positivity, which resulted in a sensitivity of 57.1% and a specificity of 75.0% for predicting breast cancer death. This cut-point resulted in a positive predictive value of 90.7%. An alternative method, recursive partitioning, identified 77% as the optimal cut-point for the training cohort to predict OS.
The ROC determined cut-point of 77.5% (rounded to 78%) was significantly associated with ERα status and breast cancer subtype in both cohorts (Supplementary Tables 2 and 3 Table   4 ). For example, for the combined training and validation cohorts, the accuracy of Decision Tree with information gain criterion in prediction of AR classes <78% and >78% was 87.27% and 90.98%, respectively (Supplementary Table 4 ).
Histological grade III and progesterone receptor (PR) negative tumors were significantly associated with low AR positivity in the training cohort (Supplementary Table 2 ). The lack of an association between AR and PR in the validation cohort (Supplementary Table 3 Table 2 ) and a 2-fold reduced risk in the validation cohort (HR=0.51, Cox regression analysis, P=0.001, Table 3 ). AR immunostaining with a cut-point of 78% was an independent predictor of OS after adjusting for all other variables significant by univariate analysis in both cohorts (Tables 2 and 3 ) but was not an independent predictor of RFS (Table 2 ). Neither the 1% nor 10% AR cut-points were significant by univariate analysis in the validation cohort (Table 3) .
AR prognosis with adjuvant therapy
Treatment information was available for the training cohort but unavailable for the validation cohort. In the training cohort, AR with a 78% cut-point predicted OS (P=0.002, log rank ERα negative and AR >78%, ERα negative and AR <78%; Figure 1E and 2E). Patients with ERα negative disease (ERα <1%) had an increased risk of death regardless of AR status, compared to those with ERα positive AR >78% tumors (training cohort: 11.5 and 10.3-fold risk, P<0.0001, Figure 1F ; validation cohort: 1.9 and 2.9-fold risk, P=0.006 and P<0.0001, Figure 2F ). The training and validation cohorts were combined for greater statistical power to assess the ability of AR to predict OS as a continuous variable or with an AR cut-point of <78% or ≥78% positivity. AR levels predicted OS in ERα positive tumors but not ERα negative tumors (Supplementary Table 5 ). When assessed by subtype, AR was an independent predictor of OS in Luminal A but not Luminal B cancers (Supplementary Table 5 ). When ROC analysis was applied to all cases or just the ERα positive cases in the combined training and validation cohorts, the optimal AR cut-point was 77 .95%.
The AR to ERα ratio is a determinant of OS in ERα positive disease
To investigate whether the relative levels of AR and ERα influenced OS, the training and validation cohorts were combined for greater statistical power and unbiased tertiles were calculated for the AR to ERα positivity ratio (<0.87, 0.87-1.05 and >1.05). Kaplan-Meier and Cox regression analyses demonstrated that patients with tumors containing comparable levels of AR and ERα (i.e. an AR to ERα positivity ratio approximating 1; range 0.87-1.05), or a predominance of AR (i.e. an AR to ERα positivity ratio >1.05) had the highest 10-year breast cancer survival outcomes (83.3% and 80.5%, respectively; P<0.0001; Figure 3) . In contrast, patients with a predominance of ERα (i.e. an AR to ERα positivity ratio <0.87) had a poorer survival outcome compared to patients with similar AR and ERα immunostaining levels (10-year breast cancer survival 71.6%; Figure 3 ; P<0.0001).
Patients with tumors that were either AR or ERα negative or lacked both receptors had a lower 10-year breast cancer specific survival rate of 53-66% (Figure 3 ; 3-fold increased risk of death, P<0.004). ROC analysis showed that the optimal cut-point for the AR to ERα positivity ratio was 0.82. However, in multivariate analyses, neither the AR to ERα ratio tertile groups nor an AR to ERα ratio cut-point of 0.82 were independent predictors of OS in the combined training and validation cohorts (Supplementary Table 6A and 6B). Consistent with this, the AR to ERα ratio did not differentiate between luminal A and luminal B ERα positive breast cancer subgroups (Supplementary Table 7 ).
Discussion
The current study demonstrates that clinical assessment of AR in addition to ERα may permit a more precise prediction of breast cancer outcome in women, particularly those with hormone sensitive disease, providing an optimal cut-point for AR is utilized. As highlighted by our comprehensive review of the literature, many published studies have investigated AR as a prognostic factor in breast cancer, but the findings have been inconsistent resulting in doubt about its clinical utility for prognostication. A critical common limitation of previous studies has been the failure to define an optimal AR cut-point for prognosis. Rather, arbitrary cut-points of 1% and 10% positivity, used to determine AR status, were typically applied to dichotomize data for prognostic testing. Herein, we provide the first robust, statistically derived cut-point for future testing of AR as a prognostic factor in prospective cohorts.
ROC analysis using two independent, well characterized breast cancer cohorts with 10-year followup demonstrated that a cut-point of 78% AR positivity, which approximated the median value, achieved the best combination of specificity and sensitivity for prediction of breast cancer survival.
This cut-point value was reinforced using recursive partitioning of the data. Ten-fold cross validation, a statistic used in supervised learning and class prediction, confirmed the robustness of the AR cut-point defined by ROC analysis. Our finding that the optimal AR cut-point approximated the median percentage positivity determined by immunostaining is consistent with 2 of 3 previous biochemical (radio-ligand binding) studies of unselected breast cancer cohorts that arbitrarily used the median AR protein level to dichotomize the breast cancer survival data (52) (53) (54) 
Tokunaga et al (7) employed an arbitrary cut-point of 75% AR positivity, which approximated the median immunostaining, to demonstrate that AR is an independent predictor of outcome in an unselected breast cancer cohort. Hence, our statistically determined AR cut-point is not without precedence in the literature concerning AR and breast cancer prognostication when all cases are considered.
AR was prognostic in this study for all breast cancer cases in both cohorts, which likely reflects its negative correlation with tumor size and proliferative capacity, regardless of ERα status as shown in this study and previously reported (3, 5, 55) . A recent meta-analysis in which AR mRNA expression was correlated with various gene signatures in large combined breast cancer cohorts strongly supports this concept (26) . Functionally, AR and ERα are hormone-activated nuclear transcription factors that regulate gene expression and are commonly co-expressed in normal and malignant breast epithelial cells (37, 56) , indicating the potential for direct cross-talk between these two sex hormone receptor signaling pathways. Indeed, antagonism between AR and ERα signaling is thought to underpin sex-specific breast development (9) . In breast cancer, this interaction and its functional consequence is likely to be perturbed by altered receptor levels and a pathological hormone milieu (8, 9, 34) .
Our data showing that a high AR cut-point is required to robustly predict survival from ERα positive disease is consistent with the concept that a minimum threshold of AR activity is required to restrain growth of ERα positive breast cancers (34, 37) . Indeed, this may explain why AR positivity tends to be higher than ERα positivity in normal and most ERα positive malignant breast tissues, even though the expression of both receptors is increased in the malignant compared to the normal state (8) . We have previously shown that exogenous AR dose-dependently inhibited ERα transcriptional activity from an AR to ERα molar ratio of 1:1 to 4:1 (37) . This finding is in accordance with another study showing that an AR to ERα ratio approximating 1 was associated with a survival advantage in a tamoxifen-treated cohort of ERα positive patients (15) . However, the same study disagreed with our finding that a predominance of AR over ERα conferred a survival advantage, reporting that an AR to ERα ratio > 2 was associated with treatment failure on tamoxifen (15) . In that study, AR positive tumors were defined as AR >0% positivity, which has only been used in 1 other immunohistochemical study (see Table 1 ), and AR alone did not independently predict outcome. Moreover, the AR=0% cases, which are well established as being associated with a poor prognosis, were included in the AR to ERα ratio <2 group. In our study, in the analysis showing that patients with tumors characterized by a predominance of ERα over AR had a reduced chance of survival, only tumors that were positive for both AR and ERα were included in the analysis. In this scenario, AR may have lost its capacity to antagonize ERα signaling, either due to insufficient expression or activation. Additionally, a recent preclinical study showed that estrogen potentially can activate AR in a non-classical manner to facilitate ERα genomic activity in breast cancer cells (17) . Hence, studies examining the prognostic value of AR in ERα positive breast cancers that included tumors with very low levels of AR expression (e.g. cutpoints of >0%, >1% or >10%) may have produced disparate results because low AR expression or insufficient activation cannot effectively oppose ERα activity or conditions are such that AR is hijacked into facilitating ERα activity. This presents a therapeutic conundrum as the latter scenario indicates an AR antagonist strategy whereas the former suggests an AR agonist strategy. While both options are supported by recent studies that have employed patient-derived xenograft models (14, 17) , the outcome of current clinical trials will provide definitive evidence regarding this controversy.
AR status did not improve the stratification of ERα negative breast cancers in terms of patient outcome, likely due to insufficient power. In a larger study, Hu et al (3) showed that postmenopausal women with ERα negative breast cancers had poor survival irrespective of AR status. Since ERα negative breast cancers are less common than ERα positive cancers and represent a very heterogeneous mix of molecular disease entities, it has been difficult to definitively identify robust prognostic factors. However, meta-analyses of studies examining AR as a prognostic factor propose that studies to determine the optimal AR cut-point for selection of patients who are likely to showing that breast tumors with high AR that were ERα positive (AR>78% ERα+) are associated with a significantly increased overall patient survival (log rank statistic=32.34, P <0.0001) when compared to the remaining tumor groups (AR<78% ERα+; AR>78% ERα-and AR<78% ERα-). (F) Cox regression analysis for OS comparing relative risk among AR and ERα sub-groups in (E); n=204. ERα+ denotes ERα >1% positive tumor nuclei; ERα-denotes ERα negative tumors. AR>78 denotes AR positivity greater than or equal to 78% and AR<78 refers to AR positivity less than 78%. HR, hazard ratio; CI, confidence interval. 
Tables
AR>78 denotes AR positivity greater than or equal to 78% and AR<78 refers to AR positivity less than 78%. HR, hazard ratio; CI, confidence interval. 
